Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
3
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
8
Teen smoking, drinking decline, while mental health, dietary habits worsen
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
North Korean leader ‘convinced’ dialogue won’t change US hostility
A new vaccine to control endemic cholera and large-scale outbreaks around the world, received approval by the World Health Organization, according to the Seoul-based International Vaccine Institute, which developed the vaccine.
Developed by the IVI, the vaccine is produced by Shanta Biotechnics, an Indian biotechnology company, with financial support from Gates Foundation, and the governments of Korea and Sweden.
The IVI said that the vaccine will help facilitate large-scale immunization since it can be administered orally, will be low cost, and is effective for children aged under six.
The IVI plans to introduce the vaccine in countries where cholera remains a major public health problem in Africa and South Asia. It estimates that there have been nearly 3 million cases requiring treatment and about 94,000 deaths due to cholera in those regions.
“In light of the devastating cholera outbreaks in Haiti, Pakistan, Nepal and in several countries of Africa, there is a clear need for a solution to halt the countless deaths and suffering,” said Dr. Christian Loucq, director general of the IVI.
“A vaccine like Shanchol should positively impact public health efforts to control cholera in these countries.”
The IVI, established in 1997 as an U.N. initiative, is an independent international health organization devoted to developing and introducing vaccines to protect the poor around the world under a treaty signed by 40 countries and the WHO.
By Lee Woo-young (wylee@heraldcorp.com)
Developed by the IVI, the vaccine is produced by Shanta Biotechnics, an Indian biotechnology company, with financial support from Gates Foundation, and the governments of Korea and Sweden.
The IVI said that the vaccine will help facilitate large-scale immunization since it can be administered orally, will be low cost, and is effective for children aged under six.
The IVI plans to introduce the vaccine in countries where cholera remains a major public health problem in Africa and South Asia. It estimates that there have been nearly 3 million cases requiring treatment and about 94,000 deaths due to cholera in those regions.
“In light of the devastating cholera outbreaks in Haiti, Pakistan, Nepal and in several countries of Africa, there is a clear need for a solution to halt the countless deaths and suffering,” said Dr. Christian Loucq, director general of the IVI.
“A vaccine like Shanchol should positively impact public health efforts to control cholera in these countries.”
The IVI, established in 1997 as an U.N. initiative, is an independent international health organization devoted to developing and introducing vaccines to protect the poor around the world under a treaty signed by 40 countries and the WHO.
By Lee Woo-young (wylee@heraldcorp.com)
